ClinicalTrials.gg
CompletedNCT04144257Updated Oct 15, 2026Results posted

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

A Phase 1/2 interventional study of [F-18]PBR06 and [C-11]Methylreboxetine in Multiple Sclerosis, sponsored by Brigham and Women's Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Brigham and Women's Hospital · Phase 1/2, Interventional, and Diagnostic

How we know

Updated Oct 15, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Multiple Sclerosis by Brigham and Women's Hospital — 4 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis · Brigham and Women's Hospital.

Started
2020
with 1 other
Phase 1/2
4 of 15
2 open now
Registered
8th of 15
by date

Among the 15 studies in Multiple Sclerosis by Brigham and Women's Hospital, this one is one of 2 that started in 2020, is one of 4 in phase 1/2, and was the 8th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 15 studies in Multiple Sclerosis by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Multiple Sclerosis by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and [C-11]MRB.

Specific Aims:

Specific Aim 1: To determine the relationship of cerebral microglial activation, as assessed by [F-18]PBR06 PET, with MS-related fatigue.

Specific Aim 2: To determine the relationship of norepinephrine transporter (NET) binding, as assessed by [C-11]MRB PET, with MS-related fatigue.

Specific Aim 3: To determine the relationship of microglial activation and NET binding, with grey matter pathology (lesion load and brain atrophy) assessed using 7T MRI, and evaluate their independent contribution in development of MS-related fatigue.

Read the detailed description

Design: This is a single center, cross-sectional study of patients with multiple sclerosis, who will each, undergo both, [C-11]MRB-PET (norepinephrine transporter binding) and [F-18]PBR06-PET (microglial activation), in addition to 7 Tesla brain MRIs. Patients will also undergo cross-sectional estimations of blood markers.

Genotype Testing:

Blood sample drawn on the initial screening visit will be used to obtain genomic DNA for genotyping for polymorphism within the TSPO gene on chromosome 22q13.2, using a Taqman assay. High affinity and medium affinity binders will be included while the low affinity binders will be excluded from the study.

PET Scanning:

During the PET scan visits, all women subjects of child bearing age will undergo a stat quantitative serum hCG pregnancy test and only women with a negative test will undergo the radiopharmaceutical injection. The radiotracers will be produced using standardized procedures. At the time of imaging, the subjects will be positioned in the gantry of a high-resolution PET/CT camera. Head alignment will be made, relative to the canthomeatal line, using projected laser lines whose positions are known with respect to the slice positions of the scanner. A head support apparatus will be used to minimize head motion.Dynamic data over 120 minutes for PET quantification will be acquired, according to previously described methods for both tracers.

MRI Scanning:

High resolution MRI scanning will be performed using the 7T Siemens MAGNETOM Terra MRI unit at Brigham \& Women's Hospital (BWH).

Serum assays:

Serum measurements for inflammatory markers and relevant neurochemicals will be performed according to established procedures.

Clinical Data

The following non-imaging, clinical data will be obtained:

Modified fatigue Impact Scale (MFIS) Fatigue Severity Status Scale (FSSS) Expanded Disability Status Scale (EDSS) Timed 25-feet walk (T25W) MS Functional Composite (MSFC) Symbol digit modalities test (SDMT) MSQOL-54 scale (QOL) Pittsburgh Sleep Quality Index (PSQI) Beck's Depression Inventory (BDI) Center for Epidemiological Studies-Depression Scale (CES-D) Hospital Anxiety and Depression Scale (HADS)

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects meeting the definition for RRMS or SPMS by International Panel (2017 McDonald) Criteria.
  • We will recruit patients with RRMS, recently diagnosed in the last 2 years. There will be no disease modifying therapy restrictions for RRMS or SPMS patients.
  • Male and female subjects age 18 to 60 years.
  • Patients able to withhold medication that may interfere with C-11[MRB] radiotracer uptake for 24 hours before the scan.

Exclusion criteria

Exclusion Criteria:

  • Relapse/ treatment in the past 4 weeks to avoid transient effects on imaging
  • Individuals with a known alternate neurologic disorder, previous head injury, or substance abuse.
  • Individuals with bipolar disease and schizophrenia
  • Concurrent medical conditions that contraindicate study procedures.
  • Women who are pregnant or nursing. Also, any woman who is seeking to become pregnant or suspects she is pregnant will be excluded from enrollment.
  • Claustrophobia
  • Non-MRI compatible implanted devices
  • Low affinity binders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Subjects diagnosed with multiple sclerosis

    We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing-remitting multiple sclerosis and 6 with secondary progressive multiple sclerosis).

    Drug: [F-18]PBR06 · Drug: [C-11]Methylreboxetine

Interventions

  • DrugPBR-06Studies of PBR-06PBR-06 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).

    Also known as: [18F]PBR06

  • Drug[C-11]Methylreboxetine

    PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).

    Also known as: [C-11]MRB

06

What researchers measure

Primary outcomes

  1. Standardized Uptake Value Ratio (SUVR)

    PET outcome measure for \[F-18\]PBR06 radioligand used to quantify microglial activation.

    Time frame: Baseline

  2. Area Under the Curve Ratio (AUCR)

    PET outcome measure for \[C-11\]MeNer radioligand used to quantify norepinephrine transporter binding in brain regions of interest (e.g, putaminal, pallidal, and white matter).

    Time frame: Baseline

Secondary outcomes

  1. Correlations Between Modified Fatigue Impact Scale (MFIS) and PET Outcome Measures

    MFIS is a fatigue rating scale. Scores range from 0-84. Higher values indicate worse fatigue.

    Time frame: Baseline

  2. Correlations Between Expanded Disability Status Scale (EDSS) and PET Outcome Measures

    EDSS is a disability rating scale. Scores range from 0-10. Higher values indicate worse clinical function.

    Time frame: Baseline

07

Results

Posted Oct 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneSubjects Diagnosed With Multiple Sclerosis
Started14
Completed10
Not completed4

Outcome measures

PrimaryStandardized Uptake Value Ratio (SUVR)

PET outcome measure for \[F-18\]PBR06 radioligand used to quantify microglial activation.

Time frame:
Baseline
Reported as:
Mean · SUVR
Standardized Uptake Value Ratio (SUVR)
SUVRSubjects Diagnosed With Multiple Sclerosis
Standardized Uptake Value Ratio (SUVR)0.78 ± 0.06
PrimaryArea Under the Curve Ratio (AUCR)

PET outcome measure for \[C-11\]MeNer radioligand used to quantify norepinephrine transporter binding in brain regions of interest (e.g, putaminal, pallidal, and white matter).

Time frame:
Baseline
Reported as:
Mean · AUCR
Area Under the Curve Ratio (AUCR)
AUCRSubjects Diagnosed With Multiple Sclerosis
AUCR - Putamen/Occipital Lobe1.01 ± 0.05
AUCR - Pallidum/Occipital Lobe0.84 ± 0.09
SecondaryCorrelations Between Modified Fatigue Impact Scale (MFIS) and PET Outcome Measures

MFIS is a fatigue rating scale. Scores range from 0-84. Higher values indicate worse fatigue.

Time frame:
Baseline
Reported as:
Number · Correlation Coefficient
Correlations Between Modified Fatigue Impact Scale (MFIS) and PET Outcome Measures
Correlation CoefficientSubjects Diagnosed With Multiple Sclerosis
Correlation between SUVR and MFIS0.65
Correlation between Putamen/Occipital Lobe AUCR and MFIS0.46
Correlation between Pallidum/Occipital Lobe AUCR and MFIS0.71
SecondaryCorrelations Between Expanded Disability Status Scale (EDSS) and PET Outcome Measures

EDSS is a disability rating scale. Scores range from 0-10. Higher values indicate worse clinical function.

Time frame:
Baseline
Reported as:
Number · Correlation Coefficient
Correlations Between Expanded Disability Status Scale (EDSS) and PET Outcome Measures
Correlation CoefficientSubjects Diagnosed With Multiple Sclerosis
Correlation between SUVR and EDSS0.74
Correlation between Putamen/Occipital Lobe AUCR and EDSS0.79
Correlation between Pallidum/Occipital Lobe AUCR and EDSS0.82

Adverse events

Collected over From enrollment to completion of study, an average of 11 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subjects Diagnosed With Multiple Sclerosis0/10 (0%)0/10 (0%)4/10 (40%)
Most frequent other events
Most frequent other events
EventSubjects Diagnosed With Multiple Sclerosis
Pain/pressure on the back of the head during the MRIMusculoskeletal and connective tissue disorders2/10
Dizziness during the MRI.Nervous system disorders1/10
Discomfort from the headrest during PET scan.Musculoskeletal and connective tissue disorders1/10
Right shoulder pain during the PET scan.Musculoskeletal and connective tissue disorders1/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Subjects Diagnosed With Multiple Sclerosis
Mean47.00 ± 8.98
Sex: Female, Male
Sex: Female, Male(Participants)Subjects Diagnosed With Multiple Sclerosis
Female8
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Subjects Diagnosed With Multiple Sclerosis
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Subjects Diagnosed With Multiple Sclerosis
Hispanic or Latino0
Not Hispanic or Latino10
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Subjects Diagnosed With Multiple Sclerosis
United States10
Expanded Disability Status Scale
Expanded Disability Status Scale(Score on the EDSS (0-10))Subjects Diagnosed With Multiple Sclerosis
Mean3.8 ± 2.1
Timed 25-Foot Walk
Timed 25-Foot Walk(Time in Seconds)Subjects Diagnosed With Multiple Sclerosis
Mean11.6 ± 14.6
Modified Fatigue Impact Scale
Modified Fatigue Impact Scale(Score on the MFIS (0-84))Subjects Diagnosed With Multiple Sclerosis
Mean34.3 ± 25.9
08

Study locations

1 site
  • Brigham MS Center, 60 Fenwood Road
    Boston, Massachusetts 02115, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Apr 2021, 13 months.

Results were first posted in Oct 2026, 5 years 6 months after primary completion.

Of 33 phase 1/2 interventional studies under Multiple Sclerosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 89. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2019
First posted
Oct 30, 2019
StartActual
Mar 12, 2020
Primary completionActual
Apr 13, 2021
CompletionActual
Apr 13, 2021
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Enrollment
10→14
Oct 15, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedCorrelations betweenBetween Modified Fatigue Impact Scale (MFIS) and PET outcome measuresOutcome MeasuresTime frame: Baseline
  • EditedCorrelations betweenBetween Expanded Disability Status Scale (EDSS) and PET outcome measuresOutcome MeasuresTime frame: Baseline
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Enrollment 10→14
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedCorrelations betweenBetween Modified Fatigue Impact Scale (MFIS) and PET outcome measuresOutcome MeasuresTime frame: Baseline
    • EditedCorrelations betweenBetween Expanded Disability Status Scale (EDSS) and PET outcome measuresOutcome MeasuresTime frame: Baseline
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04144257
Collaborators
U.S. Army Medical Research Acquisition Activity
Responsible party
TARUN SINGHAL (Associate Professor of Neurology, Brigham and Women's Hospital) — Principal investigator
First posted
Oct 30, 2019
Start date
Mar 12, 2020
Primary completion
Apr 13, 2021
Completion
Apr 13, 2021
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Tarun Singhal, MD
principal investigator · Brigham and Women's Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PBR-06

Start the discussion